



MAY 06 2008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 03/31/2007. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitution Form 1448/PTO

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/580,011
Filing Date	
First Named Inventor	Tim Fat Tam
Art Unit	
Examiner Name	
Attorney Docket Number	PT2116001

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		<i>Country Code²-Number³-Kind Code⁴ (if known)</i>			
JCH		CA 2,379,370	09-28-2003	Apotex Inc.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/580,011		
		Filing Date			
		First Named Inventor	Tim Fat Tam		
		Art Unit			
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	PT2116001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BARTFAY et al., Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron-overload, Cardiovascular Research, 1999, 43(4), pp. 892-900	
		BERGERON et al., A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One..., Blood, 1992, Vol. 79, No. 7, pp. 1882-1890	
		Crumbliss, A.L., Iron Chelation in Biology (http://www.medicine.uiowa.edu/FRRB/VirtualSchool/Crumbliss-Fe.pdf)	
		DHUNGANA et al., Fe(III) Coordination Properties of a New Saccharide-Based Exocyclic Trihydroxamate Analogue ..., Inorganic Chemistry, January 13, 2003, 42(1), pp. 42-50	
		HENDRICKSON et al, The Consequences of Chemical Bonding: Classes of Molecules, Organic Chemistry, Third Edition, 1970, McGraw Hill, p. 72	
		HERSHKO et al., The iron-loaded gerbil model revisited: Effects of deferoxamine and deferiprone treatment, J. Lab. Clin. Med., 2002, Vol. 139, No. 1, pp. 50-58	
		KING, R.E., Tablets, Capsules, and Pills, Remington's Pharmaceutical Sciences, 15th Edition, 1975, Mack Publishing Company, Easton, PA, ch. 89, pp. 1576-1607	
		KONTOGHIOGHES, G.J., Orally active a-Ketohydroxypyridine Iron Chelators: Studies in Mice, Molecular Pharmacology, 1986, 30(6), pp. 670-673	
		PERNAROWSKI, M., Solutions, Emulsions, and Suspensions, Remington's Pharmaceutical Sciences, 15th Edition, 1975, Mack Publishing Company, Easton, PA, ch. 83, pp. 1436-1460	
		PIERRE, J. L. and FONTECAVE, M., Iron and activated oxygen species in biology: The basic chemistry, BioMetals, 1999, 12, pp. 195-199	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (03-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/580,011		
		Filing Date			
		First Named Inventor	Tim Fat Tam		
		Art Unit			
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	PT2116001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RAKBA et al., Iron Mobilisation and Cellular Protection by a New Synthetic Chelator O-Trensox, Biochemical Pharmacology, 1998, 55(11), pp. 1797-1806	
		SINGH et al., Urinary Metabolic Profiles in Human and Rat of 1,2-Dimethyl- and 1,2-Diethyl-Substituted ..., Drug Metabolism and Disposition, 1992, Vol. 20, No. 2, pp. 256-261	
		TAM et al., Iron Chelator Research: Past, Present, and Future, Current Medicinal Chemistry, June 2003, Vol. 10, No. 12, pp. 983-995	
		VAN ASBECK et al., Anti-HIV effect of iron chelators: different mechanisms involved, Journal of Clinical Virology, February 2001, Vol. 20, No. 3, pp. 141-147	
		VOEST et al., Iron-Chelating Agents in Non-Iron Overload Conditions, Annals of Internal Medicine, 1994, Vol. 120, No. 6, pp. 490-499	

Examiner Signature		Date Considered	2/4/08
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.